IP Library Patent Application 11656088
Patent Application
App. No. 11/656,088

Methods of preventing or treating sinusitis with oxidative reductive potential water solution

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/656,088
Abstract

Provided is a method for preventing or treating sinusitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers. The ORP water solution can be administered alone or, e.g., in combination with one or more additional therapeutic agents.

Claims (48)

1 . A method of treating or preventing sinusitis in a patient, the method comprising administering to the patient a therapeutically effective amount of an oxidative reductive potential water solution, wherein the solution is stable for at least about twenty-four hours and the solution has a pH of from about 6.4 to about 7.8.

2 . The method of claim 1 , comprising administering the oxidative reductive potential water solution to the upper respiratory airway.

3 . The method of claim 1 , comprising contacting one or more tissues in the upper respiratory airway with the oxidative reductive potential water solution.

4 . The method of claim 1 , comprising contacting tissue in one or more cranial sinuses with the oxidative reductive potential water solution.

5 . The method of claim 4 , wherein the one or more cranial sinuses are selected from the group consisting of frontal sinuses, maxillary sinuses, ethmoid sinuses, and sphenoid sinuses, and combinations thereof.

6 . The method of claim 1 , comprising administering the oxidative reductive potential water solution to one or more ethmoid sinuses.

7 . The method of claim 1 , comprising contacting one or more tissues in the ethmoid sinuses with the oxidative reductive potential water solution.

8 . The method of claim 1 , comprising intranasally administering the oxidative reductive potential water solution.

9 . The method of claim 1 , comprising administering the oxidative reductive potential water solution through one or more openings of the mouth or nose.

10 . The method of claim 1 , comprising delivering the oxidative reductive potential water solution in the form of a liquid, spray, mist, aerosol or steam.

11 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered by aerosolization, nebulization or atomization.

12 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered in the form of droplets having a diameter in the range of from about 0.1 micron to about 100 microns.

13 . The method of claim 1 , wherein the sinusitis is acute sinusitis.

14 . The method of claim 1 , wherein the sinusitis is chronic sinusitis.

15 . The method of claim 1 , wherein the sinusitis results from an allergic reaction.

16 . The method of claim 1 , wherein the sinusitis results from asthma.

17 . The method of claim 1 , wherein the sinusitis results from an infection.

18 . The method of claim 17 , wherein the infection is by one or more microorganisms selected from the group consisting of viruses, bacteria, and fungi.

19 . The method of claim 18 , wherein the infection is by one or more viruses selected from the group consisting of coxsackie viruses, adenoviruses, rhinoviruses, and influenza viruses.

20 . The method of claim 18 , wherein the infection is by one or more bacteria selected from the group of Streptococcus pneumoniae, Haemophilus influenzae, staphylococci , non- pneumococcal streptococci, corynebacterium , and anaerobes.

21 . The method of claim 18 , wherein the infection is by one or more fungi selected from the group of zygomycetes, aspergillus , and candida.

22 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered in combination with up to about 25% of one or more carriers.

23 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered in combination with up to about 50% of one or more carriers.

24 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered in combination with up to about 75% of one or more carriers.

25 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered in combination with up to about 90% of one or more carriers.

26 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered in combination with up to about 95% of one or more carriers.

27 . The method of claim 1 , wherein the oxidative reductive potential water solution is administered in combination with up to about 99% of one or more carriers

28 . The method of claim 22 , wherein the one or more carriers is selected from the group consisting of sterile water, saline and combinations thereof.

29 . The method of claim 23 , wherein the one or more carriers is selected from the group consisting of sterile water, saline and combinations thereof.

30 . The method of claim 24 , wherein the one or more carriers is selected from the group consisting of sterile water, saline and combinations thereof.

31 . The method of claim 25 , wherein the one or more carriers is selected from the group consisting of sterile water, saline and combinations thereof.

32 . The method of claim 26 , wherein the one or more carriers is selected from the group consisting of sterile water, saline and combinations thereof.

33 . The method of claim 27 , wherein the one or more carriers is selected from the group consisting of sterile water, saline and combinations thereof.

34 . The method of claim 1 , wherein the pH of the oxidative reductive potential water solution is from about 7.4 to about 7.6.

35 . The method of claim 1 , wherein the oxidative reductive potential water solution is stable for at least about two weeks.

36 . The method of claim 1 , wherein the oxidative reductive potential water solution is stable for at least about two months.

37 . The method of claim 1 , wherein the oxidative reductive potential water solution is stable for at least about six months.

38 . The method of claim 1 , wherein the oxidative reductive potential water solution is stable for at least about one year.

39 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises cathode water in an amount of from about 10% to about 50% by volume of the solution.

40 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises cathode water in an amount of from about 20% to about 40% by volume of the solution.

41 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises anode water in an amount of from about 50% to about 90% by volume of the solution.

42 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises from about 10% by volume to about 50% by volume of cathode water and from about 50% by volume to about 90% by volume of anode water.

43 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises at least one free chlorine species selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, and combinations thereof.

44 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises from about 15 ppm to about 35 ppm hypochlorous acid.

45 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises from about 25 ppm to about 50 ppm sodium hypochlorite.

46 . The method of claim 1 , wherein the oxidative reductive potential water solution comprises from about 15 ppm to about 35 ppm hypochlorous acid, from about 25 ppm to about 50 ppm sodium hypochiorite, a pH of from about 6.2 to about 7.8, and the solution is stable for at least about one week.

47 . The method of claim 1 , wherein the oxidative reductive potential water solution has a potential from about −400 mV to about +1300 mV.

48 . The method of claim 1 , further comprising administering at least one additional therapeutic agent from the group consisting of antihistamines, decongestants, anti-infective agents, anti-inflammatory agents, and combinations thereof.

Assignments (6)
CHANGE OF NAME Recorded Jan 5, 2017
From: OCULUS INNOVATIVE SCIENCES, INC.
To: SONOMA PHARMACEUTICALS, INC.
Reel/Frame 041257/0375 →
RELEASE OF LIEN Recorded Feb 24, 2015
From: VENTURE LENDING & LEASING V, INC.
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 035090/0111 →
RELEASE OF LIEN Recorded Feb 24, 2015
From: VENTURE LENDING & LEASING VI, INC.
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 035090/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2014
From: ALIMI, HOJABR; GUTIERREZ, ANDRES
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 031992/0159 →
SECURITY INTEREST Recorded Jul 7, 2011
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING V, INC.
Reel/Frame 026619/0196 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 026619/0235 →